Amarin Raises $52M for Lipid Treatment Enterprise

Lipid therapy specialist Amarin Corp. (NASDAQ GM: AMRN) has raised $52.8 million in a convertible preferred stock offering. Amarin makes VASCEPA, which the company styles the first FDA-approved Omega-3 product. VASCEPA is designed to lower triglyceride levels without increasing levels of LDL, the "bad" cholesterol. Amarin stock was up 6.59% when he deal closed on March 6.